Navigation Links
Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Date:8/29/2013

p>Elagolix inhibits gonadotropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. To date, elagolix has been studied in over 20 clinical trials totaling more than 1,000 subjects. At the time of expected NDA filing for endometriosis, elagolix will have been studied in over 25 clinical trials and in excess of 3,000 subjects. A Phase IIb trial of elagolix for the treatment of uterine fibroids is also ongoing.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
2. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
3. Neurocrine Biosciences Reports First Quarter 2013 Results
4. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
5. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
6. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
7. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
8. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
10. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
11. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 /PRNewswire/ ... are increasing in applications as their effectiveness ... firm Kalorama Information.  Kalorama Information says that ... is the most powerful tool in proteomic ... spec; MS) through its traditional techniques has ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... abstracts of studies in its neuroscience and oncology ... the 67 th American Academy of Neurology ... , from April 18-25. The accepted abstracts feature ... in addition to investigational treatments in AbbVie,s pipeline. ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced that updated ... of the triplet combination of TELCYTA(R),(canfosfamide HCl, ... the 98th annual meeting of the American ... Preclinical studies of,cellular and molecular correlates of ...
... WIRE)--Apr 11, 2007 - Cyclacel,Pharmaceuticals, Inc. (Nasdaq: ... the company will present results of two,preclinical ... advanced drug candidates in clinical development. The ... during the upcoming,Annual Meeting of the American ...
Cached Medicine Technology:Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 2Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 3Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 4
(Date:2/28/2015)... Heart diseases are on the rise in India. ... population and 5 percent of rural adult population suffer ... of them require specialized investigation and treatment to prevent ... (CVD). , A division of Indian Business News Agency ... “Indian Coronary Stent Market Forecast to 2019”. The new ...
(Date:2/28/2015)... The Classic Denture Center , located in ... Throughout all of March patients can receive $25 off ... can help overall mouth health and give patients ... certain symptoms that suggest the denture teeth are in ... 1.    Pain, clicking, and popping in the joints, 2.    Pain behind ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... 28, 2015 Dr. Perry Patel ... area residents, recently announced a special offer for the ... treatment option for new and established patients at his Pismo ... a bright, white smile, Dr. Patel and his staff ... marked down from the regular price of $450. , ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an article ... To Steal Your Data , which stresses the ease with ... DIY phishing kit, or any kind of malware kit for ... point about how everyone’s cyber security is intertwined when it ... legitimate content management systems or blogs in order to install ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... marketing called long overdue , THURSDAY, June 11 (HealthDay ... to give the U.S. Food and Drug Administration control ... the country. , The legislation "will finally put an ... designed to addict children to its deadly products," said ...
... Brinker International, Inc. (NYSE: EAT ), announced its ... and Kennedy in bringing the restaurant industry, government and public ... has posted its nutritional information online for a number of ... to this information so they can make informed dining decisions. ...
... 11 The Department of Veterans Affairs (VA) has announced plans ... Medical Center to the Rosalind Franklin University of Medicine and ... land will enable VA to support its ongoing efforts to improve ... aligning facilities and assets," said Dr. Gerald M. Cross, VA,s Acting ...
... Combined diet, exercise and injection had best results in study ... drug normally used to treat diabetes, may also help non-diabetic ... new research has found. , Researchers divided 152 obese men ... and an average weight of 241 pounds) into two groups. ...
... , CHEYENNE, Wyo., June 11 The ,Help ... throughout the week of June 15th - 19th at various ... information on programs that provide prescription medicines for free or ... percent and having risen steadily the past 14 months, the ...
... CHICAGO (June 11, 2009) New research published in the ... of Surgeons reveals that in counties with the highest ... population was associated with a decrease in the availability and ... of emergency room visits. This research supports prior studies that ...
Cached Medicine News:Health News:Health Organizations Cheer Senate Vote on Tobacco Control 2Health News:Health Organizations Cheer Senate Vote on Tobacco Control 3Health News:Brinker International Announces Support of Senate's Agreement on Uniform Nutrition Disclosure 2Health News:Diabetes Drug Byetta May Aid Weight Loss in Obese Patients 2Health News:Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 4Health News:Study finds segregation decreases access to surgical care for minorities 2
... 3085 SP Surgical Table combines innovation and ... weighing up to 1,000 lbs. You can ... both normal and reverse orientation and have ... other patients.,The Amsco 3085 SP Table offers ...
... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: